Revised May 7, 2009

Completed Trials
Clinical Trial Collaborations
Clinical Trial Contacts
  1. Protocol: A phase I study of recombinant adenovirus vector-mediated delivery of an anti-erbB-2 single-chain (sFv) antibody gene for previously treated ovarian and extraovarian cancer patients. Human Gene Therapy. 8(2): 229-42, 1997.

    Principal Investigator: Dr. Ronald D. Alvarez

    Trial Findings: Alvarez RD, Barnes MN, Gomez-Navarro J, Wang MH, Strong TV, Arafat W, Arani RB, Johnson MR, Roberts BL, Siegal GP, Curiel DT. A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): A phase I trial. Clinical Cancer Research. 6(8): 3081-3087, 2000.

  2. Protocol: A phase I study of recombinant adenovirus vector-mediated intraperitoneal delivery of herpes simplex virus thymidine kinase (HSV-TK) gene and intravenous ganciclovir for previously treated ovarian and extraovarian cancer patients. Human Gene Therapy. 8(5): 597-613, 1997.

    Principal Investigator: Dr. Ronald D. Alvarez.

    Trial Findings: Alvarez RD, Gomez-Navarro J, Wang M, Barnes MN, Strong TV, Arani RB, Arafat W, Hughes JV, Siegal GP, Curiel DT. Adenoviral-mediated suicide gene therapy for ovarian cancer Molecular Therapy. 2(5):524-30, 2000.

  3. Protocol: Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients.

    Principal Investigator: Dr. Robert M. Conry.

    Trial Findings: Conry RM, LoBuglio AF, Strong TV, Moore SE, Allen KO, Barlow DL, Shaw DR, Curiel DT. Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients. Submitted.